Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: A pilot study

P. Queirolo, A. Morabito, S. Laurent, S. Lastraioli, P. Piccioli, P. A. Ascierto, G. Gentilcore, M. Serra, A. Marasco, E. Tornari, B. Dozin, M. P. Pistillo

Research output: Contribution to journalArticle


CTLA-4 blockade with monoclonal antibodies can lead to cancer regression in patients with metastatic melanoma (MM). CTLA-4 gene polymorphisms may influence the response to anti-CTLA-4 antibodies although few data are available regarding this issue. We analyzed six CTLA-4 single nucleotide polymorphisms (-1661A>G,-1577G>A,-658C>T,-319C>T, +49A>G, and CT60G>A) in 14 Italian MM patients and 45 healthy subjects. We found a significant association between the-1577G/A and CT60G/A genotypes and improved overall survival (Pc <0.006, Bonferroni corrected), further confirmed by the diplotype analysis (-1577&CT60 GG-AA diplotype, p <0.001). A positive trend toward an association between these genotypes and response to therapy was also observed.

Original languageEnglish
Pages (from-to)336-345
Number of pages10
JournalCancer Investigation
Issue number5
Publication statusPublished - Jun 2013



  • CTLA-4
  • CTLA-4 blockade
  • Melanoma
  • Overall survival
  • Single nucleotide polymorphisms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this